Spyros Papapetropoulos - Apr 16, 2025 Form 4/A - Amendment Insider Report for Neuphoria Therapeutics Inc. (NEUP)

Role: President and CEO, Director
Signature: /s/ Elaine Wangsawidjaja, Attorney-in-Fact for Spyros Papapetropoulos
Stock symbol: NEUP
Transactions as of: Apr 16, 2025
Transactions value $: $139,320
Form type: 4/A - Amendment
Date filed: 5/19/2025, 04:40 PM
Date Of Original Report: Apr 17, 2025
Previous filing: Jul 8, 2024
Next filing: Jun 5, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Papapetropoulos Spyros	President and CEO, Director	100 SUMMIT DRIVE, BURLINGTON	/s/ Elaine Wangsawidjaja, Attorney-in-Fact for Spyros Papapetropoulos	2025-05-19	0001832694

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NEUP	Employee Stock Option (Right-to-Buy)	Award	$139K	+27K	+215.5%	$5.16	39.5K	Apr 16, 2025	Common Stock	27K	$5.16	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares.
F2	Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested.

Content

The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares.

Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested.